Aperture will advance APRTX-001 as a potential treatment for ALS and frontotemporal dementia, with possible expansion for use ...

The ALS Association is the world's leading funder of amyotrophic lateral sclerosis (ALS) research ---- The Hoffman ALS Clinical Trial Awards ...

Recent developments in health include the FDA's new focus on expedited drug approvals, potential ALS treatment breakthroughs ...

Scientists discover a new gene therapy technique that may reverse ALS by restoring vital RNA signals, providing hope for ...

An announcement from Pharmaust Limited ( ($AU:NUZ) ) is now available. Neurizon Therapeutics Limited announced the results of its Annual General ...

The experimental therapy M102 slowed disease progression in preclinical experiments done in mouse and cell models of ALS, a ...

Researchers at Tel Aviv University led a large-scale international study that opens a new avenue for treating the fatal degenerative disease ALS, considered incurable until now. The researchers ...

Funding from the Hugh and Herbert Hoffman ALS Impact Fund will support eligible clinics nationwide and expand access to life-extending ALS care ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved RELYVRIO™ ...

NEW ORLEANS, July 22, 2025 /PRNewswire/ -- Answer ALS is proud to announce the launch of a groundbreaking collaborative initiative aimed at accelerating AI-powered drug discovery for ALS and other ...

The Food and Drug Administration (FDA) has not approved stem cell therapy for amyotrophic lateral sclerosis (ALS). However, people could participate in clinical trials involving this ALS treatment.